Advertisement

Advertisement

Breast Cancer

Pertuzumab/Trastuzumab With or Without Chemotherapy Followed by T-DM1 in HER2-Positive Metastatic Breast Cancer

In an analysis from a phase II European trial reported in JAMA Oncology, Jens Huober, MD, and colleagues found no difference in overall survival with pertuzumab/trastuzumab, with or without chemotherapy, followed by second-line ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive...

Breast Cancer

Targeted Axillary Dissection After Neoadjuvant Therapy in Node-Positive Breast Cancer

In a German prospective registry study (SenTa) reported in JAMA Surgery, Kuemmel et al found that targeted axillary dissection alone after neoadjuvant systemic therapy was associated with outcomes similar to those obtained with targeted axillary dissection plus axillary lymph node dissection in...

Breast Cancer

Breast Cancer Screening and 10-Year Net Survival in Canadian Women Aged 40 to 49

In a Canadian study reported in the Journal of Clinical Oncology, Wilkinson et al found that breast cancer screening was associated with greater 10-year breast cancer net survival among women aged 40 to 49 living in jurisdictions including mammography screening programs for this age group, compared ...

Breast Cancer
Genomics/Genetics

Researchers May Have Identified Several New Breast Cancer Susceptibility Genes

Researchers have identified genes that may be associated with breast cancer and could eventually be included in tests to identify high-risk patients, according to a recent study published by Wilcox et al in Nature Genetics. Background Currently, genetic tests for breast cancer consider a few genes...

Breast Cancer

New Challenge in Triple-Negative Breast Cancer: Optimizing the Sequencing of Treatments

New approaches are offering hope for better outcomes in metastatic triple-negative breast cancer, according to Suchita Pakkala, MD, of Emory University’s Winship Cancer Institute, Atlanta. She shared her thoughts on using PARP inhibitors and antibody-drug conjugates at the 2023 Debates and...

Breast Cancer
Gynecologic Cancers
Genomics/Genetics

Therapeutic Implications of DNA Repair Discoveries in Patients With Homologous Recombination Deficiencies

Long-molecule scars may help identify patients with BRCA1- and BRCA2-deficient cancer types, according to a recent study published by Setton et al in Nature. Background Once DNA is damaged by toxins, radiation, or normal cell division, human cells must continually fix DNA breaks to survive. When...

Breast Cancer

Locoregional Recurrence Patterns Among Molecular Subtypes of Breast Cancer

In a South Korean single-center retrospective cohort study reported in JAMA Surgery, Cheun et al identified locoregional recurrence patterns according to molecular subtypes of breast cancer among women undergoing surgery for the disease. The study involved data from 16,462 women who underwent...

Breast Cancer
Geriatric Oncology

Breast Cancer Overdiagnosis May Be Common Among Older Female Patients

Continued breast cancer screening after age 70 may be associated with a greater incidence of asymptomatic cancer, according to a recent study published by Richman et al in the Annals of Internal Medicine. These new findings suggested that overdiagnosis may be prevalent among older female patients....

Breast Cancer

Effects of BMI in Patients With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Palbociclib and Endocrine Therapy

In a preplanned analysis of the phase III PALLAS trial reported in the Journal of Clinical Oncology, Pfeiler et al found that higher body mass index (BMI) reduced the risk of neutropenia and treatment discontinuation in patients with early hormone receptor–positive breast cancer receiving adjuvant...

Breast Cancer

AI-Supported Screen Reading vs Standard Double Reading in Mammography Screening for Breast Cancer

In a Swedish study (Mammography Screening with Artificial Intelligence [MASAI]) reported in The Lancet Oncology, Lång et al found that artificial intelligence (AI)-supported screen reading was associated with a similar cancer detection rate and a lower screen-reading workload vs standard double...

Breast Cancer
Survivorship

Impact of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors

In a systematic review and meta-analysis reported in the Journal of Clinical Oncology, Bright et al found that interventions to promote adjuvant endocrine therapy adherence in breast cancer survivors were successful overall compared with control conditions, although some interventions appeared to...

Breast Cancer

Susan M. Love, MD, MBA, Breast Cancer Surgeon, Researcher, and Advocate

Susan M. Love, MD, MBA, a renowned surgeon, author, researcher, and patient advocate who dedicated her life’s work to breast cancer care, died on July 2, 2023, at her home in Los Angeles. The cause of death was recurrent leukemia. She was 75. Born in Long Branch, New Jersey, on February 9, 1948,...

Breast Cancer

Alcohol Consumption and Risk of Breast Cancer Recurrence

A report published by Kwan et al in the journal Cancer provides new information that may help oncologists answer one of the most common questions they hear from breast cancer survivors: Is it safe to drink alcohol? The findings suggest drinking alcohol is not associated with an increased risk of...

Breast Cancer

Elevated MRI Enhancement May Indicate Increased Risk of Cancer in Patients With Very Dense Breasts

A machine-learning model found that background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) may be an indicator of breast cancer risk in patients with extremely dense breasts, according to a study published by Wang et al in Radiology. Patients with extremely dense...

Breast Cancer

ASCO Awarded $11 Million to Study Oral Drug Dosing Strategies in Older Adults With Metastatic Breast Cancer Receiving CDK4/6 Inhibitors

ASCO has been awarded $11 million in research funding by the Patient-Centered Outcomes Research Institute (PCORI) to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. The study aims to address a critical evidence gap in the treatment of this...

Breast Cancer

Should CDK4/6 Inhibitors Be a First-Line Option for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer?

Two studies presented at the 2023 ASCO Annual Meeting challenge the use of CDK4/6 inhibitors as part of upfront treatment of advanced hormone receptor–positive, HER2-negative breast cancer. The first, the SONIA trial, found that first-line treatment with CDK4/6 inhibitors led to greater toxicity...

Breast Cancer

HER2-Low Status Is ‘Dynamic’ for Patients With Triple-Negative Breast Cancer

The probability of obtaining a HER2-low test result increases with the number of biopsies performed, according to a study of more than 500 biopsy samples in patients with triple-negative breast cancer. For patients originally labeled as having no HER2 expression (HER2 0), each successive biopsy...

Breast Cancer

How Does BMI Affect Cardiac Health for Patients With Breast Cancer Receiving Chemotherapy?

A study covering the northeast region of Colombia found nearly 12% of patients with a high body mass index (BMI) being treated for breast cancer at a regional center experienced cardiotoxicity during chemotherapy. The study will be presented at the upcoming American College of Cardiology Latin...

Survivorship
Colorectal Cancer
Breast Cancer
Prostate Cancer

Primary Cancer and Noncancer Mortality Among Long-Term Survivors of Solid Tumors

In a study reported in JAMA Network Open, KC et al identified factors involved with primary cancer mortality vs noncancer mortality among long-term survivors of breast, prostate, and colorectal cancers. Study Details The study included data on 627,702 patients in the Surveillance, Epidemiology,...

Breast Cancer
Issues in Oncology

Forced Displacement and Diagnosis of Cancer in Syrian Refugees

Syrian migrants, including refugees, may be more likely to be diagnosed with a more advanced stage of breast cancer at a younger age when compared with individuals from Jordan, according to a recent study published by Hazra et al in JAMA Network Open. The new findings suggest the trauma associated...

Breast Cancer

ASCO-CAP Guideline Update Confirms Previous Recommendations for HER2 Testing in Breast Cancer

In partnership with the College of American Pathologists (CAP), ASCO has affirmed findings from its 2018 practice guideline on the use of HER2 testing in breast cancer. Notably, the ASCO/CAP expert panel found there is currently no justification for a new designation of HER2 test results for...

Breast Cancer
Immunotherapy

Expert Point of View: Barbara Pistilli, MD

Barbara Pistilli, MD, Head of the Breast Cancer Unit in the Medical Oncology Department of Gustave Roussy Cancer Center, Villejuif, France, was invited to discuss the TROPiCS-02 updated analysis. She began by pointing out that the target landscape of antibody-drug conjugates is “expanding...

Breast Cancer
Immunotherapy

Extended Follow-up of TROPiCS-02 Trial: Sacituzumab Govitecan in Metastatic Breast Cancer

Additional follow-up of the phase III TROPiCS-02 trial has upheld the progression-free and overall survival benefit seen with sacituzumab govitecan-hziy compared with physician’s choice of treatment in patients with endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast...

Breast Cancer

Expert Point of View: Ines Vaz-Luis, MD, PhD

The invited discussant of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, Ines Vaz-Luis, MD, PhD, of the Breast Cancer Survivorship Group, Gustave Roussy, Villejuif, France, pointed out that the benefit of ovarian suppression or ablation in reducing breast cancer...

Breast Cancer

EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence

A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...

Breast Cancer
Issues in Oncology

Biological Aging and Radiation Therapy for Breast Cancer

Some patients who have received treatment for breast cancer may experience increased biological aging compared with those who have never been diagnosed with breast cancer, according to a new study published by Kresovich et al in the Journal of the National Cancer Institute. The findings showed that ...

Breast Cancer
Immunotherapy

Current Management of and Future Possibilities for Triple-Negative Breast Cancer

“Triple-negative breast cancer remains the most challenging subtype to treat because of its aggressive phenotype and limited treatment options,” stated Erica Michelle Stringer-Reasor, MD, who spoke at an education session on current approaches to treatment and future directions during the 2023 ASCO ...

Breast Cancer
Palliative Care

Two Studies Highlight Benefits in Quality of Life and Symptom Management With Novel Treatments of Advanced Breast Cancer

Recent improvements in overall and progression-free survival for patients with HER2-positive and estrogen receptor–positive breast cancers have not come at the expense of quality of life or symptom management, according to a pair of studies presented at the European Society for Medical Oncology...

Breast Cancer

Regional Nodal Irradiation and Locoregional Recurrence in Patients With Favorable-Risk Node-Positive Breast Cancer

In a secondary analysis from the SWOG S1007 trial reported in JAMA Oncology, Reshma Jagsi, MD, DPhil, and colleagues found low rates of locoregional recurrence irrespective of the use of regional nodal irradiation in patients with favorable-risk, node-positive breast cancer receiving radiation...

Breast Cancer
Issues in Oncology

Decimation of Gut Bacteria and Chemotherapy-Induced Weight Gain in Patients With Breast Cancer

Researchers have uncovered a potential link between chemotherapy-induced changes to gut bacteria and weight gain seen in patients with breast cancer, according to a recent study published by Walker et al in BMC Medicine. The findings may help to identify approaches to avoid obesity-related diseases ...

Breast Cancer

Expert Point of View: Kevin Kalinsky, MD, MS

Session co-moderator Kevin Kalinsky, MD, MS, the Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director of the Glenn Family Breast Center, and Director of Breast Medical Oncology at the Winship Cancer Institute of Emory University, Atlanta, offered his thoughts on PHERGain to The...

Breast Cancer

PHERGain: Adapted-Response Trial Guides Treatment With Dual HER2 Blockade Alone

The phase II PHERGain trial, which employed a response-adapted strategy in the treatment of early-stage, HER2-positive breast cancer, has shown promising results for the selective use of HER2 blockade and de-escalation of chemotherapy.1 Nearly all patients assigned to skip chemotherapy prior to...

Breast Cancer

I Didn’t Want My Past to Become My Future

When I felt a large mass in my left breast as I was drying off from a shower on Thanksgiving Day, in 2007, I instinctively knew it was cancer. My mother had been diagnosed with breast cancer when she was 38, just 7 years older than I was at the time, and died 4 years later. I was 6 when she was...

Breast Cancer
Supportive Care

Targeting Depressive Symptoms in Younger Breast Cancer Survivors

Guest Editor’s Note: Psychological distress is highly prevalent in women diagnosed with premenopausal breast cancer and has a significant negative impact on their quality of life. Thus, effective strategies are urgently needed to reduce the symptom burden. In this installment of The ASCO Post’s...

Breast Cancer

Lobular vs Ductal Breast Cancer: Distinctions in Management

As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...

Breast Cancer

Pathology Assessment During Mastectomy and Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer

Axillary management decisions made during surgery may be associated with aggressive treatment of limited nodal disease, according to data presented at a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Results of a large National Cancer Database study revealed that...

Breast Cancer

Largest Human Breast Cell Atlas to Date May Offer Insights Into Mammary Biology

Researchers have created the world’s largest and most comprehensive atlas of normal breast tissue—the Human Breast Cell Atlas—which may provide an unprecedented understanding of mammary biology and help identify therapeutic targets for diseases such as breast cancer, according to a recent study...

Breast Cancer

Amcenestrant vs Standard Endocrine Therapy in ER-Positive, HER2-Negative Advanced Breast Cancer

In the phase II AMEERA-3 trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that the selective estrogen receptor degrader amcenestrant did not improve progression-free survival vs physician’s choice of endocrine therapy in patients with estrogen...

Breast Cancer

FDA Approves Iopromide Injection for Contrast-Enhanced Mammography

Iopromide-300 and -370 (Ultravist), an iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography—making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of...

Breast Cancer
Issues in Oncology

Potential Role of ChatGPT-4 in Selecting Appropriate Imaging Tests for Breast Cancer Screenings and Breast Pain

Investigators have found that artificial intelligence (AI) language models like OpenAI’s ChatGPT may accurately identify appropriate imaging tests for breast cancer screenings and breast pain, according to a recent study published by Rao et al in the Journal of the American College of Radiology....

Breast Cancer

Guideline Update Provides New Testing and Treatment Recommendations for Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Mutations

Testing for the emergence of ESR1 mutations should be routine at disease recurrence or progression for patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer whose disease is being managed with endocrine therapy, according to an ASCO guideline rapid recommendation...

Breast Cancer

Dose-Escalated Simultaneous Integrated Boost Radiotherapy for Early-Stage Breast Cancer

In the phase III IMPORT HIGH trial reported in The Lancet, Charlotte E. Coles, FRCR, and colleagues found little difference in ipsilateral breast tumor relapse rates with adjuvant dose-escalated simultaneous integrated boost radiotherapy vs lower-dose sequential boost radiotherapy in patients with...

Breast Cancer

Adjuvant Treatment With Ribociclib Reduces Risk of Recurrence in Hormone Receptor–Positive, HER2-Negative, Early-Stage Breast Cancer

The addition of the CDK4/6 inhibitor ribociclib to endocrine therapy significantly improved invasive disease–free survival in women with hormone receptor–positive, HER2-negative, early-stage breast cancer. These results of the phase III NATALEE trial were reported by lead author Dennis J. Slamon,...

Breast Cancer

PET/CT-FDG vs Conventional Staging in Locally Advanced Breast Cancer

In a Canadian study reported in the Journal of Clinical Oncology, Dayes et al found that positron-emission tomography/computed tomography–fluorodeoxyglucose (PET/CT-FDG) improved the detection of distant metastasis vs conventional staging in patients with locally advanced breast cancer. It also...

Breast Cancer
Survivorship

Aromatase Inhibitors May Limit Effectiveness of Weight Loss Medications in Breast Cancer Survivors

Aromatase inhibitors may interfere with the efficacy of weight loss medications in breast cancer survivors, according to a new study presented by Fansa et al at the 2023 Endocrine Society Annual Meeting. Background Aromatase inhibitors are designed to block the activity of the aromatase enzyme,...

Breast Cancer
Survivorship
Geriatric Oncology

Older Breast Cancer Survivors May Experience Accelerated Aging, Worse Functional Outcomes Following Chemotherapy

Investigators have found that older breast cancer survivors—particularly those exposed to chemotherapy—may experience greater epigenetic aging and poorer outcomes than those without a history of cancer, according to a new study published by Rentscher et al in Cancer. Background Epigenetic aging...

Breast Cancer

Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and After Treatment for High-Risk Breast Cancer: Association With Recurrence and Mortality

In a study reported in JAMA Network Open, Cannioto et al found that greater adherence to cancer prevention lifestyle recommendations before, during, and after treatment for high-risk breast cancer was associated with a reduced risk of disease recurrence and all-cause mortality. Study Details The...

Breast Cancer
Colorectal Cancer
Gynecologic Cancers
Issues in Oncology

Impact of Historic Redlining Practices on Cancer Screening Rates

Although redlining was outlawed more than 50 years ago, individuals who currently live in historically redlined areas may be less likely to be screened for breast cancer, colorectal cancer, and cervical cancer than individuals who live in areas not associated with redlining practices, according to...

Breast Cancer
Genomics/Genetics

Study Evaluates Clinical Utility of Novel Liquid Biopsy-Breast Cancer Methylation Prototype Assay

A novel, automated liquid biopsy test—the Liquid Biopsy for Breast Cancer Methylation assay—may be effective at predicting early disease progression and potential survival outcomes in patients with metastatic breast cancer after as little as 1 month of treatment, according to a study published by...

Breast Cancer
Issues in Oncology

Mortality Rates From Second Cancers in Hispanic and Non-Hispanic Black Breast Cancer Survivors

Hispanic and non-Hispanic Black breast cancer survivors may experience higher rates of mortality after being diagnosed with a second primary cancer than breast cancer survivors of other ethnic and racial groups, according to a new study published by Deng et al in the Journal of the National Cancer...

Advertisement

Advertisement

Advertisement